Growth hormone replacement delays the progression of chronic heart failure combined with growth hormone deficiency: an extension of a randomized controlled single-blind study.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Whether long-term GH replacement also affects CHF progression is unknown.

Who Took Part

The study group was 158 patients.

PubMed indexes the participants as middle-aged adults, both men and women.

The study is an extension of a previous randomized, controlled single-blind trial that screened 158 consecutive CHF patients (New York Heart Association classes II to IV) and identified 63 who had GHD by the growth hormone releasing hormone plus arginine test.

Fifty-six patients were randomized to receive either GH therapy or standard CHF therapy.

How the Study Was Run

The design is described as randomized and single-blind.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

In this single-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study one party knew the assignments and the other did not.

The primary endpoint was peak oxygen consumption (VO2).

Secondary endpoints included left ventricular (LV) ejection fraction and volumes, serum amino terminal fragment of the pro-hormone brain-type natriuretic peptide, quality of life, and safety.

What Was Measured

PubMed files the paper under topics including Chronic Disease, Deficiency Diseases, Disease Progression, Growth Hormone, Heart Failure, Hormone Replacement Therapy and Human Growth Hormone.

Author keywords: GH replacement, chronic heart failure and longterm.

What This Means in Plain Language

The paper is a randomized and single-blind study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 158 patients.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2013 (JACC. Heart failure), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.